Summary:
A new clinical research study for people with ER-positive, HER2-negative breast cancer
PersevERA is a phase 3 clinical study evaluating an investigational oral hormone therapy for people diagnosed with ER-positive, HER2-negative locally advanced (recurrent or progressed) or metastatic breast cancer.
PersevERA at a Glance
- Participants: Eligible adults with locally advanced or metastatic breast cancer
- Duration: Approximately 82 months
- Administration: Taken orally during three 28-day treatment cycles
Who may be eligible?
Participants in the persevERA Study must meet the following eligibility criteria:*
- Be 18 years of age or older
- Be diagnosed with ER-positive, HER2-negative locally advanced or metastatic breast cancer
- Have not received any prior treatment with a SERD (e.g., fulvestrant)
*Additional criteria apply.